Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02163434 · ClinicalTrials.gov registry record · Phase 2
Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum
A Phase 2 study of Hyperemesis Gravidarum, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 2
- Study locations
NCT02163434 is a Phase 2 study of Hyperemesis Gravidarum that has completed, run by State University of New York at Buffalo. The registered enrollment target is 31 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT02163434, a Phase 2 study of Hyperemesis Gravidarum, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators will compare the effectiveness of gabapentin to metoclopramide for 1 week among 60 women with hyperemesis gravidarum (HG) in this randomized, double-blinded trial. After completion of the 1-week double-blind phase, subjects will be offered open-label gabapentin with rescue metoclopramide until their symptoms no longer require treatment. Enrollment will occur at the University's at Buffalo, of Rochester and of Wisconsin.
Conditions Studied
Interventions
- DRUG Gabapentin
- DRUG Metoclopramide
Study Locations (2)
New York
- University at Buffalo - Buffalo
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-06 |
| Est. Completion | 2019-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02163434
The ClinicalTrials.gov registry entry for NCT02163434 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperemesis Gravidarum appearing as the primary indexed condition, and to 2 interventions - of which Gabapentin is the first listed.
NCT02163434 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02163434 about?
NCT02163434 is a clinical study titled "Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum". The investigators will compare the effectiveness of gabapentin to metoclopramide for 1 week among 60 women with hyperemesis gravidarum (HG) in this randomized, double-blinded trial. After completion of the 1-week double-blind phase, subjects will be offered open-label gabapentin with rescue metoclop...
What is the current status of trial NCT02163434?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2014-06. Estimated completion is 2019-11.
What conditions does trial NCT02163434 study?
This clinical trial studies the following conditions: Hyperemesis Gravidarum.
What interventions are being tested in trial NCT02163434?
The interventions under investigation include: Gabapentin (DRUG), Metoclopramide (DRUG).
Who is sponsoring clinical trial NCT02163434?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02163434 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.